Similar to breast cancer where they inhibit E2 signaling, HDAC inhibitors or HDAC1/3 knockdown suppresses AR signaling in prostate cancer cells by preventing recruitment of AR coactivators, SRC1 and p300 to AR target genes (104). This evidence concerns the gene HDAC9 and prostate carcinoma.